New hope for kids with gigantism: daily shot may curb excess growth
NCT ID NCT03882034
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 25 times
Summary
This study tested a daily injection called pegvisomant in 12 children aged 2 to 18 with gigantism, a condition causing too much growth hormone. The goal was to see if the drug could safely lower hormone levels and slow abnormal growth. Participants received the drug for 60 weeks and were monitored with blood tests, imaging, and physical exams.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITUITARY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.